Uncategorized
Infobird (NASDAQ: IFBD), a business-to-business (“B2B”) artificial intelligence (“AI”) solutions company, recently announced the successful implementation of its intelligent quality inspection software-as-a-service (“SaaS”) solution with one of the leading fintech companies in China. Infobird designed and developed the system for the company upon researching and analyzing its customer service business scenarios. It then built a flexible multi-dimensional quality inspection model. A recent article reads, “The Infobird client has greatly advanced its customer service quality inspection from manual inspection by random sampling to automatic inspection, resulting in a multitude of benefits in the form of a 100% quality inspection coverage rate with improved managerial efficiencies. The employment of the SaaS system led to cutting down of services of quality inspectors, resulting in cost curtailment. The quality inspection efficiency also increased by more than 100 times.”
To view the full article, visit https://ibn.fm/Ys7he
About Infobird Software Co. Ltd.
Infobird, headquartered in Beijing, China, is a software-as-a-service provider of innovative AI-powered or enabled customer engagement solutions. For more information about the company, visit www.Infobird.com.
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at http://ibn.fm/IFBD
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
ChineseWire
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
- China-based information technology company Infobird recently launched a WeChat call center designed to incorporate WeChat’s multi-channel functionality with Infobird’s SaaS platform for recruiting and retaining customers
- Infobird’s platform uses big data and AI to create “portraits” of consumers’ expectations and needs by analyzing input from multiple channels
- WeChat became the world’s largest standalone mobile app in 2018 with over 1 billion monthly active users of its messaging, social media and mobile payment services
- Infobird’s cloud computing and AI technologies have generated more than 70 proprietary licensing rights
The growth of China’s robust economic engine and the rapid modern development of the nation’s middle and upper-middle class societies in recent years has driven both domestic and foreign companies to seek out and court the hundreds of millions of Chinese consumers connected to the economy through technological tools (https://ibn.fm/B5uv6).
Companies seeking to use their resources in the most effective manner possible to acquire and retain consumers have turned to the automated, intelligent solutions big data and artificial intelligence (“AI”) can provide through the software-as-a-service (SaaS) market. Chinese SaaS innovator Infobird (NASDAQ: IFBD) is making a name for itself through its recent Nasdaq debut as well as a growing number of retail agreements that use its technology, and on July 26 the company announced its next step with the launch of its WeChat call center.
The WeChat call center is designed to help businesses build an automated and personalized private domain traffic operation platform that will help the B2C clients achieve major upgrades while drawing on the the advantages of the powerful WeChat ecosystem for interacting with customers.
WeChat is a Chinese multi-channel messaging, social media and mobile payment app that became the world’s largest standalone mobile app in 2018 with over 1 billion monthly active users (https://ibn.fm/n9wNn). Infobird’s WeChat call center brings the functionality of corporate WeChat to Infobird’s multi-channel customer interaction platform with “an exclusive private domain traffic ecosystem for enterprises through four steps” that include attracting customers, retaining customers, keeping customers actively engaged and successfully managing the customer service interactions of company personnel, according to the Google translation of the company’s Chinese news release (https://ibn.fm/pLmqK).
Using private domain traffic for the development of long-term customer relationships has become a necessary path to company growth. The SaaS industry in China was valued at $3.3 billion last year after growing 43.5 percent from the year before (https://ibn.fm/dJT7T).
Infobird has created a single platform to meet the needs of consumers and businesses by using big data and AI to analyze input from multiple channels and then generate portraits or profiles that represent each user, their expectations and their needs.
The platform provides the means for companies to understand their customers more completely and accurately, which makes it possible for the companies to employ precision marketing in e-commerce and physical stores, incorporating Infobird’s product into the companies’ infrastructure in an essentially seamless manner.
Infobird is focused on SMEs, demystifying software and automation in business processes. The advent of the COVID-19 pandemic last year expanded remote-work demands exponentially for businesses from small family operations to large corporations, and Internet cloud-based technology has stepped in to fill the need.
For more information, visit the company’s website at www.Infobird.com/en/index.html.
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer
ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
Electric technology has come quite a long way since the Tesla Roadster, built using a heavily modified Lotus Elise chassis, first hit the roads more than a decade ago. Electric vehicles (“EVs”) now use dedicated EV platforms, are larger, have bigger batteries and, in many cases, support fast charging. Efforts to increase range by making EVs more efficient, especially regarding to how they use energy, has led car makers to solar energy. Theoretically, solar panels could be used to supplement and even provide power to the onboard battery, giving drivers more range.
The American Solar Challenge is a biennial event that sees participants design, build and then drive solar-powered cars in an endurance challenge across the country. The MIT Solar Electric Vehicle Team were this year’s winners, taking first place after its solar car Nimbus beat eight other cars in the Single Occupancy Vehicle (“SOV”) category. Entirely designed and built by MIT students, Nimbus travelled a whopping 1,109 miles at an average speed of 38.4 miles an hour equipped with a solar array that supplemented the power provided by its battery pack.
This year’s competition was unique; instead of being a timed event, as it has traditionally been for years, it was based on the total distance each entry travelled. The teams had to travel from Independence, Missouri, to Las Vegas, New Mexico, and they were allowed to drive additional miles within each of the race’s three stages as long as their batteries had enough juice. Nimbus, which has been in the making for three years, surpassed the closest runner-up by more than 100 miles.
The MIT team spent three years designing, building and refining its solar vehicle, spending hours upon hours at the MIT Edgerton Center’s machine shop. Test drives included driving Nimbus around the greater-Boston area as well as to Salem, Massachusetts, and even Cape Cod. Team members also drove to Palmer Motorsports Park in Palmer, Massachusetts, in the spring to practice various race components before finally heading to the Formula Sun Grand Prix in Topeka, Arkansas, for the final test runs.
After performing a series of qualifying challenges to qualify for the race, Nimbus placed second after driving 239 laps around the track in three days (597.5 miles). The 2021 American Solar Challenge saw Nimbus travel with a caravan of seven vehicles, including a scout vehicle and a lead car as well as a chase vehicle for the strategy team, a transport truck and trailer, a media car, and a support vehicle carrying food, supplies and camping gear.
Nimbus performed admirably, but the team still has a few glitches to work on. The vehicle’s aerodynamic shape and light weight made it energy efficient, and with adequate sunlight, it could travel up to 40 miles per hour without using energy from the battery. This is the kind of technology that, once perfected, will grant electric vehicles much longer ranges while relying on clean, renewable energy. The next American Solar Challenge will take place in 2022.
The success of the MIT team points to the fact that companies such as Ideanomics Inc. (NASDAQ: IDEX) may soon not have to look very far for investment opportunities since the possibilities in the EV sector are still vastly untapped.
NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Flora Growth Corp. (NASDAQ: FLGC), an internationally focused cannabis brand builder, boasts a portfolio that spans several verticals, including pharmaceuticals, textiles, cosmetics, and food and beverage — each with a thoughtful brand designed to resonate with its intended end customer. From Flora Lab SAS and Flora Beauty to KASA Wholefoods and Hemp Textiles & Co., each of its brands prioritizes natural ingredients and value-chain sustainability, consistent with its mission. Though the company is currently organically growing market share for its existing brand portfolio, it is also seeking revenue-generating acquisitions that offer an accretive distribution network to amplify growth. As such, a recent article reads, “Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.” To date, Flora has announced two major transactions: the acquisition of Koch & Gsell and investment in Hoshi International. “Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Columbia, is currently licensed to cultivate 247 acres of cannabis. Flora Growth is uniquely positioned to capitalize on Columbia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.”
To view the full article, visit: https://cnw.fm/UVENe
About Flora Growth Corp.
Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at http://cnw.fm/FLGC
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
- Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange
- Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO
- Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline
Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than C$120 million, including the C$34 million raised during the company’s latest equity financing round.
“During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space,” said Cybin CEO Doug Drysdale. “We believe the molecules we have under development may have the potential to transform the treatment landscape and fill current unmet treatment needs for various psychiatric and neurological conditions. We look forward to sharing updates as we advance our pre-clinical and clinical programs and continue the scientific exploration that we believe will ultimately provide safer and more effective treatments for those suffering with mental illness and addiction issues.”
Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline. The company has started the next phase of its digital therapeutics platform designed to better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for both pre- and postpsychedelic treatments.
Cybin also signed an exclusive R&D collaboration agreement with TMS NeuroHealth Centers Inc., a wholly owned subsidiary of Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH), which runs 129 outpatient mental health service centers in the United States. Based on the agreement, Cybin and Greenbrook will establish Mental Health Centers of Excellence that will focus on facilitating research and development of innovative psychedelic compound-based therapeutics for patients suffering from depression.
Finally, Cybin announced that is has begun scaling up its European operations and research activities with several academic and clinical research organizations; the company is also working to transfer its intellectual property assets to its recently formed, wholly owned Ireland subsidiary. The volume of Cybin’s IP is growing as well, with the company’s patent portfolio now numbering 13 filings. Those filings cover novel psychedelic compounds, integration of delivery platforms, methods of use in psychiatric indications, and drug-discovery pipeline of modified and novel ergolines, tryptamines and phenethylamines.
In addition to these key operational highlights, Cybin also posted cash and cash equivalents reaching C$55.1 million for the quarter, boosting the company’s current cash position to C$82.5 million. Those funds are an invaluable resource for the company as it works to progress its clinical pipeline and achieve vital business initiatives. The company is dedicated to revolutionizing mental health care through the use of psychedelic therapeutics and proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical device; the device, which has been tested and evaluated extensively, features AnPac’s proprietary Cancer Differentiation Analysis Technology (“CDA”). The company has reported that all preclinical trials and tests conducted through July 2021 have produced positive results. Approval of the NMPA application would allow the device to be used to assist in the diagnosis of 11 different types of cancer, including lung, esophageal, gastric, rectal, colon, liver, breast, cervical, thyroid, pancreatic and brain cancers. The filing also includes a number of cancer types that do not yet have generally accepted biomarkers. The company anticipates that after registration testing of the CDA device, clinical trials at multiple hospitals will start in 2022. “We are extremely pleased with our current achievements and this significant progress in the commercialization efforts of our multicancer CDA technology,” said AnPac Bio CEO and chair Dr. Chris Yu. “Successful completion of this preclinical study for our CDA device and reaching the registration testing stage is a major milestone. This multicancer detection medical device is an important product of our company that we believe has significant advantages over currently marketed technologies. Once this medical device is approved for commercialization by the NMPA, it will also be an important revenue source for AnPac Bio, and we believe that it has considerable market potential. We will continue to accelerate the product registration process for this medical device, as well as work towards marketing our CDA-based tests as Laboratory Developed Tests (‘LDTs’) in the U.S.”
To view the full press release, visit https://ibn.fm/qVWnH
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA-registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021.
AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at http://ibn.fm/ANPC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Company signed agreement with Premier Distribution Services to distribute entire Alkaline88(R) bottled water line
- PDS network includes more than 800 gyms, sports nutrition stores, personal training studios and smoothie bars
- “Great partnership for both parties,” says WTER CEO
The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) continues its pattern of steady success with its most recent distribution announcement: the company has signed an agreement with Premier Distribution Services (“PDS”) to distribute WTER’s entire Alkaline88(R) bottled water line to more than 800 gyms, sports nutrition stores, personal training studios and smoothie bars (https://cnw.fm/74bCj). The company, now sitting atop the list of the largest independent alkaline water companies in the country, has seen consistent growth for the past seven quarters.
“This is a wonderful opportunity for the company as Premier Distribution Services will be carrying all of our Alkaline88 bottled waters in coolers across the country,” said Ricky Wright, president and CEO of The Alkaline Water Company. “It will help us introduce and drive the trial of our new 2-liter, aluminum and flavor-infused SKUs. It will also allow for the chilled on-premise purchase of the country’s favorite premium gallon water, Alkaline88. This is a great partnership for both parties. PDS’s clients will be able to offer health-conscious gym-goers the Smooth Hydration(TM) of Alkaline88, the Clean Beverage(TM). While PDS continues to execute their growth plan, we’ll expand with them in health and fitness venues across the country.”
With distribution centers in Florida, Nevada and Texas, PDS is preparing to open new centers in the South and Midwest. The company’s short-term strategic plan is projected to more than double its existing locations before the end of the year.
The growth that WTER anticipates from its PDS partnership aligns nicely with the increased brand awareness and product demand the company expects to see as it rolls out its newest marketing campaign. “As we plan to mobilize our first broadly distributed traditional marketing campaign with Shaquille O’Neal later this year, more and more people will be looking for our brand as their go-to choice to rehydrate during their workouts,” said Wright. “The timing couldn’t be any better.”
Basketball Hall of Famer and entertainment icon O’Neil joined the company earlier this year as an equity partner and board member; he also serves as a marquee brand ambassador for Alkaline88 (https://cnw.fm/zlKZd).
“Shaquille O’Neal’s track record as a basketball champion and Hall of Famer has translated into similar successes in business and corporate partnerships. His reputation as an astute investor, larger-than-life brand partner, and phenomenal ambassador makes this partnership extremely exciting,” said WTER chairman Aaron Keay. “We want to welcome Shaquille to the company’s advisory board and believe his positive presence and global outreach will enable Alkaline88 to aggressively push our growth trajectory even faster.”
Alkaline88 is known for its superior hydration with a perfect 8.8pH balance. The brand was developed to deliver a smooth taste that encourages consumers to drink more and fully hydrate, and the company is dedicated to purity, quality, and value. The water’s ingredient deck is simple, easy to understand, and free of buffers. Dubbed “the clean beverage,” Alkaline88 ionized water contains just two pure ingredients that customers trust — water and Pink Himalayan Rock Salt.
For more information, visit the company’s websites at www.TheAlkalineWaterCo.com and www.a88CBD.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is focused on lessening the environmental burden caused by tree debris on landfills around the U.S. According to Solid Waste Environmental Excellence Performance (“SWEEP”), the U.S. is on course to run out of landfill space in the next 15 years (https://ibn.fm/PuKZN). “Sustainable Green Team’s solutions are rooted in sustainability and based on vertically integrated operations,” reads a recent article. “In the event of a storm, SGTM’s team is deployed from a mobile command center to designated sites to strategize with national partners. . . . Next, its tree services division and fleet of trucks and machinery cut and gather tree debris for collection sites. From there, the processing division takes over, using the tree debris as feedstock that is turned into a variety of organic, next-generation mulch products that are subsequently sold to landscapers, installers and garden centers. In short, a downed tree isn’t used for another layer in a landfill; it is recycled into a premium product for SGTM’s municipal, commercial and residential customers. Better still, it helps in the efforts to prevent deforestation.”
To view the full article, visit https://ibn.fm/JAh6Z
About Sustainable Green Team Ltd.
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit https://ibn.fm/ZdiFf.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide life sciences and other key industries, today announced continued strong financial results for the second quarter ended June 30, 2021. In addition, the company provided a business update and offered guidance for the remainder of FY 2021. Among the highlights, the company reported a 127% increase in total revenue for Q2 2021 to $608,900 compared to $268,200 for Q2 2020, as well as a 178% increase in instrument sales to $337,400 compared to $121,400 for Q2 2020. “We are delighted to have followed our strong first quarter results with even stronger results in the second quarter,” said PBI’s Director of Sales and Marketing John B. Hollister. “Requests for instrument systems have increased significantly since the beginning of the year, purchases of consumable products started to pick up appreciably near the end of the second quarter, and interest in our BaroFold services has leaped forward into exciting new growth opportunities. In particular, we are pleased to report that demand for our pressure-based instruments and services continued to strengthen throughout the quarter and the year-to-date. We are looking forward to a busy and highly successful second half of 2021.”
To view the full press release, visit https://ibn.fm/4qqb3
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- PlantX recently announced that its wholly owned UK-based subsidiary, Bloombox, has partnered with Disney in a co-branded campaign
- The campaign, aimed at promoting Bloombox products and celebrating the release of Disney’s new adventure-filled film, Jungle Cruise, will feature the launch of exotic plants, a treasure hunt, and a social media campaign
- According to PlantX CEO Lorne Rapkin, the collaboration legitimizes the company’s presence in the plant-based space, supporting the fact that it is indeed a true player in the space
- The company considers the partnership an opportunity to celebrate plants and their integral role and impact across the film industry
In a recent interview with Steve Darling from Proactive, newly appointed PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) CEO Lorne Rapkin noted that the company has accelerated its position thus far in part through exciting, accretive acquisitions. These acquisitions have provided “a really nice covering of all different verticals currently, and now we are just looking to enhance that” (https://ibn.fm/peOcp).
In what appears to be a fulfillment of the commitment to enhance coverage, PlantX recently announced a partnership between its wholly owned subsidiary, Bloombox Club Limited (“Bloombox”), a UK-based e-commerce platform that sells and delivers indoor plants, and The Walt Disney Company Limited, a UK-headquartered subsidiary of The Walt Disney Company (The Walt Disney Company (NYSE: DIS). The partnership encompasses a new co-branded campaign to promote Bloombox products and celebrate the release of Disney’s new adventure-filled film, Jungle Cruise (https://ibn.fm/91MgE).
As part of the campaign, Bloombox will promote the film’s release by providing exotic plants that go hand in hand with the film, including a new Amazonian plant collection that features Jungle Cruise-inspired terrariums. Bloombox will also give members of its wellness community access to a 10% discount – through the code “JUNGLE10” – on its Amazonian plants, including Jungle Cruise-inspired terrariums, snaky trailing plants, and exotic trees.
The campaign will also include a “Hunt for the Healing Tree” treasure hunt on Bloombox’s website, as well as promotion on social media.
“Bloombox’s collaboration with Disney is truly a momentous opportunity to celebrate plants and their integral role and impact across the film industry,” commented PlantX Founder Sean Dollinger. “We are beyond thrilled to have Disney’s support in sharing the Bloombox exotic plant collection with our community.”
Bloombox CEO Laura Dinnage noted that the company, which believes that connecting with nature is invaluable for all ages, was excited to get involved with Disney’s campaign and introduce a new generation to plants. She further intimated that the new Jungle Cruise-inspired terrarium is the perfect activity for kids this summer and that the company has many more exotic plants that have just launched at Bloombox.
“It’s so exciting for us at the company, in the first 18 months of being in operation, to have a company like the largest entertainment company in the world, Disney, to really want to partner with a company like PlantX. It legitimizes our presence in the plant-based space,” Lorne noted in the Proactive interview.
Lorne further stated that while PlantX has also partnered with other great vendors and leaders in the e-commerce space, including Walmart (NYSE: WMT) and Hudson’s Bay, this specific partnership with Disney buttresses the fact that the company is indeed a true player in the plant-based space.
PlantX, a high-growth technology company, is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, brick-and-mortar stores, and a home delivery system for recipes, meals, products, and more.
For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality (“AR”) for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events, has integrated its next-generation ad technology with social media channels, including SNAP, Facebook and Instagram. This integration strengthens and broadens the company’s 3D/AR ad reach. Previously NexTech customers could tap into Google’s immense network, but with this new advancement, NexTech users can deliver 3D ads for other social media applications, including SNAP, Facebook and Instagram. This enhanced feature allows NexTech to leverage the full spectrum of audiences across the web and social media. “We are now fully positioned to take advantage of the fastest-growing segment in the AR industry 3D/AR advertising,” said NexTech CEO Evan Gappelberg in the press release. “With SNAP, Facebook Instagram and as previously announced our ability to deliver 3D/AR ads into the Google Display Network we now can reach a global ad audience of any demographic. With our ability to create 3D content at scale now combined with this global audience reach I believe we are perfectly positioned to accelerate our advertising revenue in the AR space.”
To view the full press release, visit https://ibn.fm/mrSeh
About Nextech AR Solutions Corp.
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.
Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, please visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Kaival Brands (NASDAQ: KAVL), a company focused on growing and incubating innovative and profitable products into mature and dominant brands, was featured in a recent equity research report. The coverage, launched by Argus Research, an independent investment research firm, highlights innovative vaping and tobacco-free nicotine delivery solutions manufactured by Bidi (R) Vapor LLC, for which Kaival Brands is the exclusive global distributor. “In our view, Kaival Brands is well positioned to expand sales of BIDI (R) nicotine delivery products. The company launched the BIDI (R) Stick in the U.S. in early 2020 and plans to launch a second product, the BIDI (R) Pouch, in 4Q21. The company is also expanding internationally, particularly in China, and developing a line of CBD products,” the report reads. “We think that Kaival Brands’ market cap near $150 million does not adequately reflect prospects for the expanded market adoption and distribution of BIDI (R) products. Based on our analysis using EV/sales multiples, our fair value estimate for KAVL is $22 per share, well above current levels.”
To view the full press release, visit https://ibn.fm/0ZX6M
About Kaival Brands Innovations Group Inc.
Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own, or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products currently manufactured by Bidi (R) Vapor LLC, a leader in disposable electronic nicotine delivery systems (“ENDS”), and is poised to expand internationally. For more information about the company, visit www.KaivalBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids. The company is creating a pipeline of drug candidates to treat various diseases with high unmet medical needs. “In a move to grow its market presence and strengthen its operations, the company announced that it had entered into a non-binding letter of intent (“LOI”) to acquire BayMedica Inc.,” reads a recent article. “This announcement followed the two parties’ reciprocal research collaboration agreement back in November 2020, which saw them collaborate on several projects since. The agreement allowed BayMedica to assess particular elements of InMed’s proprietary IntegraSyn(TM) approach in producing cannabinoids. In addition, InMed began a preclinical investigation of different compounds selected from BayMedica’s extensive library of proprietary cannabinoid analogs, designed to be developed to treat human diseases. While making the announcement, Eric A. Adams, the president and chief executive officer (“CEO”) of InMed, noted: ‘We are very excited about the prospect of continuing to work with BayMedica and the potential to build a leading rare cannabinoid company together.’”
To view the full article, visit: https://ibn.fm/Ltfiv
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at http://ibn.fm/INM
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
President Joe Biden will probably go down in history as an instrumental figure in the growth of America’s electric vehicle (“EV”) industry and the fight against runaway climate change. Biden, who took office this year, quickly unveiled a gargantuan infrastructure bill that would dedicate billions of dollars toward developing an extensive network of public electric vehicle charging stations.
With green, renewable energy and zero-emission vehicles being a major part of his agenda, Biden recently signed an executive order requiring that 50% of the vehicles sold in America must be electric by 2030. The Biden administration’s green-energy strategy would first restore and strengthen the mileage standards that were present during former President Barack Obama’s reign but were weakened by the Trump administration.
The administration would then draft stringent emission standards for passenger vehicles as well as heavy-duty trucks that would levy stiff penalties against auto makers that do not reduce their carbon emissions. Coupled with the installation of hundreds of thousands of charging stations, this would compel auto makers to ramp up the production of electric vehicles and encourage drivers to ditch their internal combustion engine vehicles for zero-emission electric cars.
America’s pursuit of electrification will have varied effects on both local and foreign auto makers. For Tesla, which received a life-saving $465 million loan to develop and manufacture the Model S back when Biden was vice president, it means good news. The California-based company has produced more than two-thirds of the battery electric vehicles (“BEVs”) on U.S. roads, and it is poised to sell at least 2.3 million EVs by 2025.
On the other end of the spectrum, foreign car maker Toyota Motors, which won’t start selling BEVs in America until next year, may have trouble penetrating the market. Speaking of international auto makers, Chinese carmakers also have an opportunity to expand into the American market as the push for battery-powered vehicles gains more steam.
Although Tesla still dominates the U.S. electric vehicle market, foreign companies may provide stiff competition to local carmakers and carve out a section of the expanding market for themselves during Biden’s time in office. Local carmakers will still have to catch up to Tesla, especially when it comes to production volume.
Unlike Tesla, which relies solely on revenue from electric vehicle sales, Ford Motors, General Motors, and Volkswagen still draw most of their revenue from internal combustion engine (“ICE”) vehicle sales despite having sold tens of thousands of EVs. Lucid Motors and Rivian, which are also based in America and are set to release their first EVs this year, could also take advantage of the recent electric vehicle mandate. Peter Wells, director of the Center for Automotive Industry Research at Cardiff Business School, says the mandates will put pressure on auto makers that have been slow to embrace electrification. This includes Chrysler, Jeep and Ram, which are owned by Stellantis and still do not have BEVs. Such companies will either have to adapt to the changing landscape or suffer the consequences of not adhering to emission standards and EV mandates.
With companies such as Ideanomics Inc. (NASDAQ: IDEX) making strategic investments into the electric vehicle industry, it may not be long before the favorable government policies, efforts of private firms and attitude changes in the public combine and result in an accelerated uptake of EVs.
NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
FingerMotion (OTCQX: FNGR) recently announced its financial results for the three months ending May 31, 2021 (“Q1 2022”). The company generated a revenue of $6 million, which included contributions from its SMS & MMS, Telecommunications Products & Services, and Big Data Businesses. “The SMS & MMS business recorded a growth in revenue of $1.81 million or 77% compared to Q1 2021; the Telecommunications Products & Services business recorded a revenue growth of $1.34 million or 341% compared to Q1 2021,” reads a recent article. The company also recorded revenues of $98,715 or 198% in quarter-over-quarter growth in its Big Data division. According to FingerMotion CEO Martin Shen, Q1 2022 marked the second quarter of Big Data revenues, and the company expects it to eventually outpace its other existing revenue streams. “The CEO of FingerMotion said that the first quarter generated $6.00 million in revenue and represented the fourth consecutive quarter of record revenue.”
To view the full article, visit https://ibn.fm/OsNIF
About FingerMotion Inc.
FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. It is one of only a few companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers that can be resold to consumers. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve over 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, visit www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at http://ibn.fm/FNGR
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
ChineseWire
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
A study conducted by researchers from NeuRA and the University of New South Wales Sydney has found that individuals with chronic pain have a neurotransmitter imbalance in the area of the brain that is responsible for regulating emotions. The study was published in the “European Journal of Pain.”
Estimates show that more than three million individuals in Australia are plagued with chronic pain, which can affect many parts of an individual’s life; more than half of these individuals also experienced depression and anxiety disorders. The researchers hypothesize that the neurotransmitter imbalance could be making it more difficult for these individuals to control their negative emotions, noting that the persistent pain may be causing the chemical disruption.
The study’s senior author, associate professor Sylvia Gustin, who is also a psychologist and neuroscientist, states that chronic pain can influence an individual’s beliefs, feelings and behaviors, explaining that researchers had found out that the pain was linked to a reduction in an inhibitive neurotransmitter known as GABA, which is found in the medial prefrontal cortex.
Inhibitive neurotransmitters weaken signals while excitatory neurotransmitters usually amplify them. In addition to helping regulate an individual’s emotions, neurotransmitters also balance messages and help cells communicate. GABA is the primary inhibitory neurotransmitter in the central nervous system (“CNS”) and is found in the area of the brain where emotional regulation happens, known as the medial prefrontal cortex, which helps soothe an individual’s emotions.
For their study, the scientists recruited 48 participants, half of whom had experienced some form of chronic pain. The researchers utilized advanced neurological imaging to scan for the presence of GABA in each participant’s medial prefrontal cortex.They discovered that in comparison with a control group, the participants who suffered from chronic pain had considerably lower GABA levels.
Gustin explained that a reduction in GABA levels meant that cells in the brain couldn’t communicate to each other, which in turn amplified the participant’s thoughts, emotions and actions. This is the first time the link between reduced GABA levels and chronic pain has been translated to human studies, having already been discovered in animal studies.
In a prior study, Gustin and her team of researchers discovered that glutamate levels were lower in individuals with chronic pain. These low levels of glutamate were also associated with increased feelings of negative thinking, worry and fear. Glutamate is the primary excitatory neurotransmitter in the CNS. The researchers note that this disruption may compromise an individual’s ability to feel positive emotions, which isn’t easily restored once lost.
The growing understanding of how the brain works may help companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are seeking to find remedies to some of the most debilitating cancers affecting the CNS and the brain without impacting the normal functioning of the brain regions targeted by the treatment.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Cybin subsidiary achieved certain milestones as outlined in acquisition agreement
- Adelia brought numerous advantages to company
- Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO
Cybin’s (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin.
Cybin closed on the acquisition of Adelia late last year, with the company noting several key advantages gained through the transaction (https://ibn.fm/KZusD). In part, the benefits include novel psychedelic molecules that diversify Cybin’s development portfolio and provide access to multiple future indications; a range of technologies related to novel therapeutics, delivery methods and therapeutic regimens, including six patent applications; an expanding library of psychedelic derivative drug-development candidates, with the first lead compounds slated to enter clinical studies this year; and seasoned leaders who bring extensive clinical and commercialization experience with major drugs, including Allegra (fexofenadine), Sabril (vigabatrin), Anzemet (dolasetron) and Vaniqa (eflornithine). In addition, Cybin strengthened its presence in the United States with ownership of Adelia’s operating development facility in the epicenter of the Boston biotechnology center.
“We are thrilled to join forces with Adelia,” said Cybin CEO Doug Drysdale. “We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects. Adelia’s expertise across multiple molecules and multiple indications could potentially give Cybin the ability to address gaps across a larger domain.”
At the time of the acquisition, Adelia had built an impressive reputation as an innovative biopharmaceutical company committed to addressing unmet mental health needs through developing proprietary psychedelic therapeutics with improved dosing efficacy and therapeutic indices. Adelia’s leadership team had worked with pharmaceutical companies including Johnson & Johnson, GlaxoSmithKline, Sanofi, Roche, Pfizer and Eli Lilly; they also had impressive academic research affiliations, including with MIT, Harvard, Stanford, Yale and Northeastern University.
Since the acquisition, the Cybin and Adelia teams have been focused on a three-pillar development strategy, including a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; efficient drug delivery to enhance dosing control; and a potential novel treatment regimen.
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibility for CYBN to obtain patent coverage in 153 countries and, if approved, allow the company to file future national applications into treaty member jurisdictions. The company filed the applications under the Patent Cooperation Treaty (“PCT”). One of the patent applications concerns a group of proprietary compounds that the company has identified as important for further evaluation toward selection as potential therapeutics. The other application regards claims and disclosures toward other proprietary novel psychedelic compounds, including compounds with positive research data, that meet the company’s internal research metrics. Cybin asserts that these applications will strengthen its CYB005 program and provide compositions for additional evaluation in future research programs. “Cybin is dedicated to finding treatments for therapy resistant psychiatric indications as we believe these will provide patients and their medical providers with new avenues to address this significant unmet need. We appreciate the continued dedication of our team to identify and progress our research phase programs toward pre-clinical evaluation,” said Cybin CEO Doug Drysdale in the press release.
To view the full press release, visit https://ibn.fm/kmKVM
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- CDC reports epilepsy is growing problem, 3.4 million people afflicted in the US
- According to report, adult cases rose from 2.3 million to 3 million between 2010 and 2015, pediatric cases increased 450,000 to 470,000 over same period
- Brain Scientific produces patented devices that can be used to provide instant EEG tests to millions of US hospital patients each year
More Americans are suffering from epilepsy than ever before, according to a report by the Center for Disease Control (“CDC”) that states that at least 3.4 million people live with the disorder in the United States (https://ibn.fm/PmF2b). Brain Scientific (OTCQB: BRSF), a New York City based commercial stage healthcare company, aims to address the problem with two FDA-cleared products that can be used to provide instant electroencephalogram (“EEG”) tests to millions of patients subject to seizures in US hospitals each year.
According to Brain Scientific’s corporate presentation (https://ibn.fm/IQ6xG), roughly four million emergency department and one million ICU patients are possibly subjected to seizures each year, and that number is expected to rise significantly. The CDC confirms the rising incidence of the disease with statistics from 2015 stating that adult cases rose from 2.3 million to 3 million between 2010 and 2015, and pediatric cases increased 450,000 to 470,000 over the same period.
“Millions of Americans are impacted by epilepsy, and unfortunately, this study shows cases are on the rise,” said CDC Director Brenda Fitzgerald, M.D. “Proper diagnosis is key to finding an effective treatment – and at CDC we are committed to researching, testing, and sharing strategies that will improve the lives of people with epilepsy.”
With patents already approved in the United States, China and Europe, Brain Scientific’s first commercialized devices – the NeuroCap(TM) and NeuroEEG(TM) – offer low-cost, disposable and portable alternatives to existing time-intensive and costly solutions. The NeuroCap is a disposable pre-gelled EEG headset that features 22 electrodes and 19 active EEG channels that adhere to the international 10-20 system, and the NeuroEEG is a compact, portable, and cost-effective clinical-grade wireless EEG amplifier. Used together both devices can acquire, record, display and transmit electrical brain activity in nearly any setting, including urban emergency departments, intensive care units, community and rural hospitals, neurology practices, primary care/internal medicine clinics, pain management clinics, sleep labs, nursing homes, and mobile diagnostic and treatment clinics.
Brain Scientific intends to take its devices beyond on-site brain diagnostic imaging with the use of cloud-powered technology and artificial intelligence (“AI”) and machine learning (“ML”) algorithms that will enable precision diagnosis by neurology specialists.
Founded in 2015, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. went public in 2018. The Company is dedicated to developing innovative, cost-effective, and portable medical devices that aim to expand the neurology market and make brain diagnostic imaging increasingly accessible to a large range of diverse, rapidly growing markets.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The past few years have seen the cannabis industry expand from only cannabis flower and edibles to all kinds of concentrates and infused beverages. Thanks to constantly improving technology, the average cannabis consumer has a wide variety of products to choose from, and at the moment, cannabis-infused drinks are enjoying a surge in popularity. But because cannabinoids such as THC and CBD, which are the chemical compounds responsible for cannabis’ effects, are not water soluble, players in the cannabis industry needed to find a way to infuse cannabis into beverages that ensured consistent product quality and user experience.
Nano-emulsification turned out to be the best option. Since cannabinoids are highly fat-soluble, they readily bond with oils and fats. While this may work great for creating edible cannabis products using cannabutter and cannaoil, beverages are a different story entirely. Not only do cannabis companies have to infuse cannabis into beverages, but they also have to ensure those beverages have a good taste and texture that stay consistent throughout the entire product line. Emulsion provides an effective means of turning raw cannabis into consistently smooth, high-quality beverages over the long term.
The process involves breaking down the cannabinoid of choice — either THC, CBD, or both — into tiny, microscopic particles and mixing those particles with a substance called an emulsifier, which helps the cannabinoid oil dissolve in water. Simply put, an emulsifier is made of two parts, with one part binding to the oil and the other binding to the water. Once the microscopic oil particles have bonded with the emulsifier, the cannabis emulsion is added to the water base ensuring a seamless marriage between the cannabinoids and water.
The result of this emulsification technology is that cannabis beverages have become much better than they used to be when they first hit the market. Lynden Henderson of Outbound Brewing says that when he first encountered a cannabis-infused beverage, it was chunky with bits of cannabis still floating throughout the drink, and had an unpleasant consistency. The experience inspired him to create his own line of cannabis beverages with colleagues at Outbound Brewing, where they leveraged nano-emulsification to develop consistently smooth drinks with a pleasant texture.
Consistency is especially crucial as users will not make repeat purchases if different bottles of the same drink have different tastes and textures. However, despite all emulsion has done for cannabis beverages, it still has limitations. Emulsions react poorly when exposed to certain packaging materials and harsh thermal conditions, or even when they are exposed to the air. Technology is constantly evolving, fortunately, and as cannabis companies further develop emulsification, they will hopefully find a solution for these issues.
Emulsion techniques are evolving rapidly, and companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are pushing the possibilities to the edge as they make infused drinks.
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in the study who used Vivos’ FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms; that is officially defined as patients in post treatment having an Apnea Hypopnea Index (“AHI”) score of less than 5. According to the announcement, before the study, 20 patients had severe OSA. Following the study, none of the patients reported worsening of their OSA symptoms, with 3 still reporting severe OSA, 12 reporting moderate OSA, 4 reporting mild OSA and 1 reporting no OSA. Of the 18 patients who began the study with moderate OSA, 64% reported an average percent improvement in AHI score. “By addressing maxillary palatal deficiencies, we believe Vivos’ treatment protocols represent an improvement over CPAP and mandibular advancement devices, known as MAD, with 27% of the study participants reporting a complete resolution of their OSA symptoms,” said Vivos chair and CEO Kirk Huntsman in the press release. “These measurements are taken without a Vivos appliance in the mouth, whereas MAD measurements are taken with the appliance in place. The more detailed data now available from this study confirms that the Vivos device works well for many patients, with the study showing very strong and statistically significant evidence for an increase in airway volume and transpalatal width (p<0.00001). We know the investment community and other interested parties have been looking for more real-world data about our devices, so we are pleased to share this more detailed study summary and its positive results.”
To view the full press release, visit https://ibn.fm/EbLXS
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective for more than 19,000 patients worldwide by more than 1,250 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) announced that, in only two months, its flagship product TAAT(TM) has been picked up for distribution in seven new U.S. states; the most recent states carrying the product are Alabama, California, Florida, Michigan and Mississippi. A few weeks ago, the company signed a distribution agreement that included Georgia; Illinois is also now carrying TAAT products. These states join Ohio, where the product was originally launched. TAAT tobacco-free and nicotine-free alternative to traditional cigarettes is also available online through the company’s e-commerce operations. In addition, the company has announced plans for its game-changing product to be available in the United Kingdom and Ireland. “An unchanging fact about consumer products is that building and growing long-term market share is a marathon, not a race,” said TAAT CEO Setti Coscarella in the press release. “From the consumer perspective, new products come and go from store shelves all the time. What the consumer does not always see is what goes on behind the scenes, which is what we have been busy with over the past several months between setting up our production infrastructure, building a wholesale distribution network, and establishing a marketing strategy to optimally position TAAT in front of smokers aged 21-plus across the United States. We took a relatively patient approach to introducing TAAT to Ohio, followed by Illinois and Georgia. . . and now that we’ve gotten the hang of what it takes to launch in new states, we have been able to expedite the process through our new distribution partners. This has enabled us to add new distribution of TAAT in seven states over just two months, which I believe is a promising indicator with respect to our mission to become a brand known worldwide in the USD $814 billion global tobacco industry.”
To view the full press release, visit https://ibn.fm/RzmA1
About TAAT Global Alternatives Inc.
TAAT Global Alternatives has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide life sciences and other key industries, has announced its participation in the Emerging Growth Conference taking place on Aug. 18, 2021. The real-time, interactive investor conference will feature 10 companies, presenting for 15-45 minutes each. PBI’s president and CEO, Richard T. Schumacher, is presenting at the event, briefly expanding on the company’s recent announcement that its new eco-friendly, agrochemical subsidiary (PBI Agrochem Inc.) has received over $1,000,000 in purchase orders in its first month of operations.
To view the full press release, visit https://ibn.fm/cdhRm
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that on Aug. 17, 2021, the stockholders approved an amendment to the company’s certificate of incorporation. The amendment, effective Aug. 17, 2021, increased the number of authorized shares of company common stock from 100,000,000 to 200,000,000. According to the update, the approval was granted at the special meeting of stockholders convened on Aug. 10, 2021, and adjourned to Aug. 17, 2021.
To view the full press release, visit https://ibn.fm/KL4Vf
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Nextech AR signed a definitive agreement to acquire UK-based spatial computing company ARWAY Ltd. in a deal that allows it to become a metaverse company
- Nextech announced it had begun integrating HoloX into Microsoft’s HoloLens2, with the integration expected to enable users to navigate the application through eye-tracking and hand gestures
- The company also announced Ryerson University had ordered an additional 35 AR labs for its biology, chemistry, and biochemistry departments
- Nextech is intent on creating shareholder value by integrating the amazing technologies it has created into a single platform that revolves around the metaverse
Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), a company bridging physical and digital worlds through its augmented reality (“AR”) platforms, believes that utilizing live streaming human holograms will result in an explosion of new use cases, as the holograms are destined to play a significant role in global entertainment, commerce, and learning (https://ibn.fm/EQwGH). Given the recent developments at Nextech, this belief is surely becoming a reality.
Nextech announced August 10 it had signed a definitive agreement under which it will acquire UK-based spatial computing company ARWAY Ltd. (“ARway”) for approximately $1 million in an all-stock transaction, as well as hire the key founders Baran Korkmaz and Nikhil Sawlani. The acquisition provides Nextech with the technology, in the form of a spatial mapping platform, that allows it to become a metaverse company (https://ibn.fm/ZfcFy).
ARway is a Unity-based spatial mapping platform that uses AI to scan and recognize surroundings for hyper-accurate location-based 3D mapping, providing users with an Augmented Reality Software Kit (“SDK”) to frame the digital world in a few minutes. This 3D mapping technology and its AR cloud, combined with Nextech’s scalable solutions for HoloX Human Holograms, AR advertising, AR portals, and AR e-commerce, position NTAR as a leader in the race to the metaverse.
In describing the concept of the metaverse during an interview published on the company’s YouTube channel (https://ibn.fm/tIHfM), Nextech CEO Evan Gappelberg likened it to a more experiential AR cloud, further noting that it constitutes persistent augmented reality (“AR”) experiences. “When you think about the top of the mountain in the world of AR, the metaverse is the top of the mountain. There’s really nothing above the metaverse; it is the highest activity or business opportunity that we can actually pursue,” he stated.
Facebook (NASDAQ: FB), Epic Games, Microsoft (NASDAQ: MSFT), and others have all identified the metaverse as the future of the internet and computing itself. However, according to Gappelberg, the metaverse is nothing exciting without the content. This is why the company sees it as an opportunity, leading to the focus on creating mini-metaverses – Nextech aims to populate the metaverse with content such as products and holograms (through HoloX).
“We think that the mini-metaverse business use case is here to stay, and the implications for future growth are significant. Nextech’s mini-metaverse offering will be available to brands and companies that want to create mini-multiverses based on a geolocation like museums, corporate headquarters, theme parks, sports stadium, university campuses, and more,” explained Gappelberg.
Further, as an integral part of Nextech’s mini-metaverse vision, the HoloX, its mixed reality (“MR”) human hologram solution expected to launch in Q3 2021, recently received a major boost when the company announced August 5 that it had begun integrating HoloX into Microsoft’s HoloLens2. Through this implementation, users will be able to navigate the application through eye-tracking and hand gestures thanks to supported gesture controls across HoloX’s UI and UX (https://ibn.fm/nkl71).
“We are starting with Microsoft as they are clearly targeting HoloLens at corporations and the government, places where we already have customer relationships, and we see very specific use cases for our holograms,” said Gappelberg.
The HoloLens initiative is being designed to provide a more realistic feeling of human hologram presence, beyond what other in-market solutions are capable of currently. Nextech sees the project as an important building block that sets it up for future success.
Nextech also announced it had received from Ryerson University, a globally recognized leader in higher education with over 46,000 students, an order for an additional 35 AR labs for its biology, chemistry, and biochemistry departments. Once these labs are complete, the institution will have one of the largest known AR immersive learning programs globally (https://ibn.fm/4NT8V).
“These new labs are in addition to the fifty labs developed for the 2020/2021 school year and the further AR labs produced through the RALE AR Lab Builder Program, a Government of Ontario Initiative in Partnership with Ryerson University and Nextech AR and will be available province-wide to institutions of higher education in 2022,” reads the press release.
Nextech is availing AR to education institutions through EdTechX, a Microsoft Azure-based platform that enables education institutions to add valuable, immersive digital experiences to learning.
With EdTechX and HoloX being just some of several amazing technologies Nextech has created so far, the company, which aims to become a leader in the AR space, believes that integrating such technologies in one unified metaverse-centric platform will create tremendous value for its shareholders.
For more information, visit the company’s website at www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Company’s patented DehydraTECH(TM) technology is showing the potential of reducing healthcare costs by improving oral medication administration – using capsule and pill form over injection administration
- Lexaria’s offering could potentially offer accelerated regulatory filing with the FDA and other regulators around the world
- The company sub-licenses its DehydraTECH technology for the delivery of fat-soluble active molecules and drugs while also operating four subsidiary companies
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, recently announced results from an anti-viral drug molecular characterization study performed by the National Research Council (“NRC”). Results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with Lexaria’s patented DehydraTECH(TM) technology. The use of DehydraTECH could preserve the ability of this form of drug delivery to qualify for an accelerated regulatory filing with the United States Food and Drug Administration (“FDA”), plus other regulators around the world.
DehydraTECH provides a potential for cost savings to the health care system by delivering anti-viral drugs more effectively through oral administration. Medication delivery through pill form instead of a shot could potentially help governments or health insurance companies save billions of dollars in administration costs.
Chris Bunka, CEO of DehydraTECH, says that DehydraTECH’s speed and efficacy in delivering a bigger fraction of the drug into the patient’s bloodstream are a result of the technology allowing the drug to bypass the liver and instead enter blood circulation via the lymphatic system.
“One of the reasons people hate taking any drugs is side effects. It might cause diarrhea, headaches, sleepiness, but because (with DehydraTECH) we can use a smaller quantity of drug to achieve the same result, side effects go down,” Bunka further explained (https://cnw.fm/5g8Td).
Lexaria is currently focused on the applications of DehydraTECH for the administration of hypertension medication but the technology has multiple applications to improve absorption rates for substances ranging from nicotine and cannabinoids to anti-viral medication, including COVID-19 applications. After finalizing current clinical studies on hypertension, the company plans to work with antivirals to help people who need them, especially where vaccination availability is low.
The company also sub-licenses the DehydraTECH technology for the delivery of fat-soluble active molecules and drugs. There are currently four subsidiary companies that Lexaria is focusing on, which include different commercial opportunities in their respective industries. These subsidiaries include Lexaria Pharma Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp., and Lexaria Canpharm Corp.
- Lexaria Pharma Corp. – investigates new products for hypertension, antivirals, and other drug classes
- Lexaria Nicotine Corp. – 16.67% owned by Altria Ventures Inc. and investigates the oral, non-combusted tobacco-derived nicotine product format opportunities
- Lexaria Hemp Corp. – pursuing business-to-business opportunities with cannabinoids, including cannabidiol (“CBD”) from hemp
- Lexaria Canpharm Corp. – state-of-the-art Health Canada-licensed lab capable of developing novel psychotropic cannabinoid formulations for potential commercialization in federally legal sectors
Hill Street Beverage Company Inc. (TSX.V: BEER) is one of the companies that sub-licenses the DehydraTECH technology from Lexaria. With the company’s alcohol-free wine popularity, Hill Street Beverage is fueling other strategic priorities, including Hill Avenue Cannabis, using Lexaria’s DehydraTECH technology (https://cnw.fm/9HNfy). Craig Brinkley, Co-CEO of Hill Street, stated that “The acquisition of the global usage rights for patented DehydraTECH from the Lexaria group of companies, aimed at growing our cannabis business worldwide, has also mobilized the company to expand our geographic footprint across all of our business lines including the new global export strategy for alcohol-free beverages.”
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About HempWire
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.HempWire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer
Do you have a questions or are you interested in working with HW? Ask our Editor
HempWire (HW)
Denver, Colorado
www.HempWire.com
303.498.7722 Office
Editor@HempWire.net
HempWire is part of the InvestorBrandNetwork.
Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products by Bidi(R) Vapor LLC, is in full support of rules and regulations governing the electronic nicotine delivery systems (“ENDS”) industry; the company also applauds efforts to enforce those regulations. This support is rooted in Kaival Brands’ own commitment to safeguard youth as well as the confidence it has in providing a safe ENDS product for adult consumers. The BIDI(R) Stick is a top-quality disposable ENDS that complies with all regulations and offers adult consumers a consistent vaping experience. In a show of its support, Bidi Vapor officials recently met with several federal agencies, including U.S. Food and Drug Administration, the Federal Trade Commission, the Bureau of Alcohol, Tobacco, Firearms and Explosives, and the Customs and Border Protection, to encourage increased enforcement. Kaival and Bidi also encourage retailers to focus on youth-access prevention and promotion of compliant brands. “We place enormous importance on our integrity and our brand name,” said Kaival Brands founder and CEO Nirajkumar Patel in the press release. “At Kaival Brands, we have built a state-of-the-art, compliance-driven set of detailed protocols around the quality of our product and where and to whom we sell it. We are confident that our model is well suited for an environment in which regulatory oversight and enforcement is far greater than it is today. In fact, not only are we ready for increased regulation and enforcement, we both encourage and welcome it.”
To view the full press release, visit https://ibn.fm/7sexK
About Kaival Brands Innovations Group Inc.
Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Commercial EV Company Ideanomics Inc. recently completed an investment agreement that will grant it a 30 percent ownership stake in Germany’s Prettl Electronics Automotive (“PEA”)
- PEA is testing an innovative high-power EV charging infrastructure solution it has developed and expects to market in 2023, strengthening Ideanomics’ efforts to fulfill its EV strategy
- The company also recently named a new executive chairman of the board and a new vice chairman of the board who will help it scale its synergistic businesses
New York-based commercial electric vehicle company Ideanomics (NASDAQ: IDEX) continues advancing its focus on the EV market as a solution to concerns about energy consumption and living standards worldwide. In June the company completed its $65 million acquisition of US Hybrid and on Aug. 2 Ideanomics announced its investment in Germany’s Prettl Electronics Automotive (“PEA”).
Prettl Electronics Automotive is part of an industrial company operation that manufactures and distributes components and systems for the automotive, energy, and electronics industries. Ideanomics’ strategic investment of €7.5 million (about $9 million) grants the company a 30 percent ownership stake in Prettl and exclusive sales and distribution rights for its charging infrastructure products and solutions in North America, according to the company’s news release (https://ibn.fm/slKIm).
“The opportunity to work with Prettl brings together two companies with a global perspective for what is required to bring EV Mobility solutions to global markets. The PEA team’s innovative approach, both in terms of potential to deploy high-power charging infrastructure and the dynamic load balancing of charging by energy requirements at an individual vehicle level, is among the most progressive EV charging solutions we have seen,” Ideanomics CEO Alf Poor stated in the news release. “PEA fulfills a critical component of our EV enablement strategy, and we look forward to supporting them as both an investor and as a regional partner.”
In conjunction with Ideanomics’ January acquisition of Wireless Advanced Vehicle Electrification (“WAVE”), which is a U.S.-based provider of inductive (wireless) charging solutions for medium and heavy-duty EVs, the Prettl investment strengthens Ideanomics’ charging infrastructure solutions for rapid deployment with or without grid connectivity, using modular technology.
The agreement also grants Ideanomics access to the expertise of automotive and power electronics industries personnel associated with PEA’s parent company the Prettl Group. The US Hybrid acquisition provides additional synergy under Ideanomics’ mission to “reduce commercial fleet greenhouse gas emissions through advanced EV technologies and forward-thinking partnerships,” building on US Hybrid’s electric powertrain components and fuel cell engines for medium and heavy-duty commercial fleet applications (https://ibn.fm/7WZtz).
Recent years have seen tremendous growth in consumer willingness to pay for technology designed to reduce the harmful effects of pollutants on the earth’s climate. Internal combustion engine emissions, in particular, have raised global concerns and spawned new efforts to advance electric-driven automotive technology in the world’s marketplace for private and commercial vehicles (https://ibn.fm/f5bdK).
“We recently launched the transformation of Ideanomics as we vertically enter the exciting EV and hydrogen fuel cell space. … I am thrilled for what’s yet to quickly come,” newly appointed Executive Chairman of the Board Shane McMahon, a former executive over World Wrestling Entertainment’s digital media and publishing divisions, stated (https://ibn.fm/1GVsQ).
Along with the announcement of McMahon’s new position, Ideanomics announced that three-time CEO Jim Cassano will become the new vice chairman as the company continues to position itself to scale its existing synergistic businesses in the EV space.
For more information, visit the company’s website at www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FRA: E4X2) has reported that it is drilling 1,828 g/t silver equivalent over more than five meters at its Platosa Mine in Durango, Mexico. Additional highlights of the report include 2,368 g/t AgEq over 1.6 meters in EX21UG597 and 1,481 g/t AgEq over 2.5 meters in EX21UG601. In addition, the company noted that the drilling results from underground continue to define mineralization in areas ahead of production at the 623, NE-1 and NE-1S Mantos as well as outside of the current mine plan. The drilling into the 623 and NE-1 Mantos specifically improve understanding and confidence, company officials observed, and extend mineralization in these areas. Excellon will continue to test target areas ahead of production. The company also noted that its drill core samples are prepared and assayed by SGS Minerals Services in Durango, Mexico. “Drilling at Platosa continues to define high-grade mineralization ahead of production,” said Excellon senior vice president of geology and corporate development Ben Pullinger in the press release. “Additionally drilling into areas previously defined by historical surface holes is upgrading our confidence in the grade and tenor of mineralization and expanding the mineralized envelope around 623 and NE-1.”
To view the full press release, visit https://ibn.fm/iT2OE
About Excellon Resources Inc.
Excellon Resources has a vision to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes the following: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. For more information about the company, please visit www.ExcellonResources.com.
NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at http://ibn.fm/EXN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
At the onset of the pandemic, restrictions on moving around were implemented, with social distancing and other measures being taken to avoid virus spread. As people have adjusted to a “new” normal, fewer and fewer individuals have been returning to their physicians for their annual cancer screenings. Cancer screening is basically getting checked for cancer by your physician before you begin displaying any symptoms.
Regular screening may find colorectal, cervical and breast cancers in their early stages when treatment will be more effective, in comparison to late-stage diagnoses. Estimates from the Centers for Disease Control and Prevention show that the gross number of cancer screenings received by its early-detection program has declined by 83% for cervical cancer and more than 85% for breast cancer, since April of last year. The National Cancer Institute also revealed that over 800 screening appointments for lung cancer at its Cancer Center in the University of Cincinnati were cancelled in just a month.
This is worrying, as experts particularly recommend lung cancer screening for individuals who are at high risk.
Experts also point out that the best way to find and diagnose breast cancer in its early stages when it’s easier to treat is through a mammogram. Mammograms are low-energy X-rays that are used to examine the breast.
For cervical cancer, physicians recommend a PAP test, which is conducted on a sample of cells obtained from the cervix. The test checks for any abnormal cells that may indicate cervical cancer, which is caused by the human papillomavirus (“HPV”). HPV is the most common sexually transmitted infection and has no cure. The disease has more thann 100 types that are divided into high-risk and low-risk subtypes. At least 14 of these types are high risk, with experts noting that HPV type 16 and 18 cause about 70% of precancerous cervical lesions and cervical cancers.
Cervical cancer is the fourth most common cancer across the globe. However, its chance of being cured is high if detected early, which is why women are advised to begin getting PAP smears at age 21. If no abnormal cells are detected, your doctor may advise you to get the PAP smear test done every three years.
Physicians advise against delays in getting screened for cancer, especially for survivors. This is because some cancers recur and may become even more aggressive.
Early cancer detection has a huge impact on survival rate and undoubtedly saves lives. So if you’ve been postponing your routine screening, make an appointment with your physician today.
The importance of screening for and detecting cancer as early as possible has prompted many firms such as AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to develop novel ways to detect cancer even before a single tumor has formed so that patients can have a fighting chance of beating the condition.
NOTE TO INVESTORS: The latest news and updates relating to AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) are available in the company’s newsroom at https://ibn.fm/ANPC
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
